Dexcom announced that it’s entering its next era with the appointment of president and CEO Jake Leach, who assumed his expanded responsibilities on January 1.

Leach’s tenure begins with prominent appearances—his first public engagement as CEO will be as CES 2026 on January 7, where he will join a mainstage panel alongside leaders from Dexcom partners ŌURA and Rimidi. They will examine the impact of continuous health monitoring for users, clinicians, and the healthcare system.

He will also deliver the opening presentation at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 12, where he will present his vision for Dexcom and outline key milestones in 2026. Leach will also share updates taking place in the company’s portfolio.

The company is revamping the Stelo app to continue making accurate glucose health information more consumer-friendly. The company made significant investments in AI-enabled features to personalize insights and the user experience, including more capabilities around food logging like macronutrient information.

After the initial launch of the G7 15 Day CGM system, it began shipping to pharmacies in early January 2026. The company also added coverage for several million people across the world over the past two years.

“I’ve had the honor of playing a role in shaping Dexcom’s industry-defining innovation since joining the company more than 20 years ago. From building the technology as an engineer in my early days, to advancing global scale to meet our long-term growth demand as COO, it’s an honor to step into the role of CEO during such a pivotal moment for the business—and a growing global metabolic health crisis,” said Leach. “I look forward to further advancing Dexcom’s long legacy of empowering people to take control of health.”

He assumes the role from Kevin Sayer, who spent the last decade guiding the company through record growth. Under Sayer’s leadership, Dexcom grew from about $250 million to over $4.6 billion in annual revenue and pioneered the CGM category with a long list of industry firsts.

This includes the first approval to replace fingersticks in treatment decisions, the first approval to send glucose data directly to smartphones, and the first CGM cleared for use in the U.S. without a prescription, among other accomplishments.